» Articles » PMID: 22679224

Interleukin-1 Receptor Antagonist is Beneficial After Subarachnoid Haemorrhage in Rat by Blocking Haem-driven Inflammatory Pathology

Overview
Journal Dis Model Mech
Specialty General Medicine
Date 2012 Jun 9
PMID 22679224
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Subarachnoid haemorrhage (SAH) is a major contributor to the burden of stroke on society. Treatment options are limited and animal models of SAH do not always mimic key pathophysiological hallmarks of the disease, thus hindering development of new therapeutics. Inflammation is strongly associated with brain injury after SAH in animals and patients, and inhibition of the pro-inflammatory cytokine interleukin-1 (IL-1) represents a possible therapeutic target. Here we report that a rupture of the middle cerebral artery in the rat produces heterogeneous infarct patterns similar to those observed in human SAH. Administration of the IL-1 receptor antagonist (IL-1Ra) reduced blood-brain barrier breakdown, and the extent of breakdown correlated with brain injury. After SAH, haem oxygenase-1 (HO-1) was strongly expressed around the bleed site and in the cortex and striatum, indicating the presence of free haem, a breakdown product of haemoglobin. HO-1 expression was also found in the same regions as microglial/macrophage expression of IL-1α. The direct effect of haem on IL-1α expression was confirmed in vitro using organotypic slice culture (OSC). Haem-induced cell death was dependent on IL-1 signalling, with IL-1Ra completely blocking cellular injury. Furthermore, stimulation of mouse primary mixed glial cells with haem induced the release of IL-1α, but not IL-1β. Thus, we suggest that haem, released from lysed red blood cells (RBCs) in the subarachnoid space, acts as a danger-associated molecular pattern (DAMP) driving IL-1-dependent inflammation. These data provide new insights into inflammation after SAH-induced brain injury and suggest IL-1Ra as a candidate therapeutic for the disease.

Citing Articles

The Comparative Effects of Anakinra and Tocilizumab on Inflammation and Cerebral Vasospasm in an Experimental Subarachnoid Hemorrhage Model.

Kilic G, Engin B, Halabi A, Tuncer C, Sungur M, Alpay M Medicina (Kaunas). 2025; 60(12.

PMID: 39768906 PMC: 11728348. DOI: 10.3390/medicina60122025.


dipeptides activate the NLRP3 inflammasome.

Rivers-Auty J, Hoyle C, Pointer A, Lawrence C, Pickering-Brown S, Brough D Brain Commun. 2024; 6(5):fcae282.

PMID: 39229486 PMC: 11369816. DOI: 10.1093/braincomms/fcae282.


Emerging Treatments for Subarachnoid Hemorrhage.

Findlay M, Kundu M, Nelson J, Cole K, Winterton C, Tenhoeve S CNS Neurol Disord Drug Targets. 2024; 23(11):1345-1356.

PMID: 38409689 DOI: 10.2174/0118715273279212240130065713.


Animal Welfare Aspects in Planning and Conducting Experiments on Rodent Models of Subarachnoid Hemorrhage.

Becker K Cell Mol Neurobiol. 2023; 43(8):3965-3981.

PMID: 37861870 PMC: 11407738. DOI: 10.1007/s10571-023-01418-5.


Early Brain Injury and Neuroprotective Treatment after Aneurysmal Subarachnoid Hemorrhage: A Literature Review.

Li X, Zeng L, Lu X, Chen K, Yu M, Wang B Brain Sci. 2023; 13(7).

PMID: 37509013 PMC: 10376973. DOI: 10.3390/brainsci13071083.


References
1.
Vergouwen M, Ilodigwe D, Loch Macdonald R . Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke. 2011; 42(4):924-9. DOI: 10.1161/STROKEAHA.110.597914. View

2.
Matz P, Weinstein P, Sharp F . Heme oxygenase-1 and heat shock protein 70 induction in glia and neurons throughout rat brain after experimental intracerebral hemorrhage. Neurosurgery. 1997; 40(1):152-60; discussion 160-2. DOI: 10.1097/00006123-199701000-00034. View

3.
Kono H, Karmarkar D, Iwakura Y, Rock K . Identification of the cellular sensor that stimulates the inflammatory response to sterile cell death. J Immunol. 2010; 184(8):4470-8. PMC: 3094104. DOI: 10.4049/jimmunol.0902485. View

4.
Simard J, Kent T, Chen M, Tarasov K, Gerzanich V . Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007; 6(3):258-68. PMC: 2725365. DOI: 10.1016/S1474-4422(07)70055-8. View

5.
Emsley H, Smith C, Georgiou R, Vail A, Hopkins S, Rothwell N . A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005; 76(10):1366-72. PMC: 1739363. DOI: 10.1136/jnnp.2004.054882. View